Experience with use of recombinant activated factor VII.
Divanon F, Hecquard C, Borel-Derlon A
J Clin Pharm Ther 2002;27(2):133-138.
Review by
Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high responding inhibitors.
O’Connell N, McMahon C, Smith J, et al.
Br J Haematol 2002;116(3):632-635.
Review by Aldouri M
Successful use of recombinant factor VIIa for hemostasis during total knee replacement in a severe hemophiliac with high-titer factor VIII inhibitor.
Carr ME, Loughran TP, Cardea JA, Smith WK, Kuhn JG, Dottore MV
Int J Hematol 2002;75(1):95-99.
Review by
Inhibition of fibrinolysis by recombinant factor VIIA in plasma from patients with severe hemophilia A.
Lisman T, Mosnier LO, Lambert T, et al.
Blood 2002;99(1):175-179.
Review by
Use of recombinant factor VIIa in hereditary bleeding disorders.
Poon MC
Curr Opin Hematol 2001;8(5):312-318.
Review by M. Aldouri
Recombinant activated factor VII (RFVIIa): Characterization, manufacturing, and clinical development.
Jurlander B, Thim L, Klausen NK, et al.
Semin Thromb Hemostasis 2001;27(4):373-383.
Review by M. Aldouri
NATA: Network for the Advancement of Patient Blood Management, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and other healthcare professionals.
Sitemap
Contact us
- secretary@nataonline.com
-
NATA
Rue de l’Industrie 24
1040 Bruxelles - VAT: 0781668659